EUVIMEDEUVIMED entdecken
Crossref

Owners’ experiences of administering meglumine antimoniate injections to dogs with leishmaniosis: An online questionnaire study

Marja K de Jong, Demy van Eijk, Femke Broere, Christine J Piek

Veterinary Record · 01.06.2024 · 194 (11)

DOI: 10.1002/vetr.4089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary Record, online erschienen am 29.05.2024. Verfasst von Marja K de Jong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Meglumine Antimoniate, Dog Diseases, Leishmaniasis, Antiprotozoal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study examined the experiences of owners of dogs with leishmaniosis who treated their dogs with daily subcutaneous meglumine antimoniate injections. The owners' perceived ease of administering the injections, the occurrence of problems and the effects on the owners and on the dog‒owner bond were evaluated.

Methods

Dogs prescribed meglumine antimoniate as a treatment for leishmaniosis were identified using the database of the veterinary pharmacy of the Faculty of Veterinary Medicine, Utrecht University. An online questionnaire was sent to the owners of these dogs to evaluate the perceived ease of administering the injections, the occurrence of problems and the effects on the owner and the dog‐owner bond.

Results

Responses were received from 64 dog owners. Most respondents (78%) reported that administering the injections was not difficult. Pain or the development of nodules at the injection site was reported in 50% and 40% of the dogs, respectively. Polyuria was reported in 44% of the dogs. Some owners reported that administering the injections had a negative impact on their psychological wellbeing (20%), and some would have liked more veterinary support (11%).

Limitations

Some questions were answered by a limited number of people, and their responses may not be representative.

Conclusion

Dog owners remain highly motivated to persevere with meglumine antimoniate treatment and are willing to administer the injections themselves. The availability of active support when needed during the therapy cycle may further improve their acceptance of and confidence in giving the injections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meglumine AntimoniateDog DiseasesLeishmaniasisAntiprotozoal AgentsDogsAnimalsSurveys and QuestionnairesHumansMaleFemaleOwnershipMeglumineOrganometallic CompoundsInjections, Subcutaneous

Substanzen

Meglumine AntimoniateAntiprotozoal AgentsMeglumineOrganometallic Compounds

Autor:innen und Institutionen

  • Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Zitieren

APA

de Jong, M. K., van Eijk, D., Broere, F., & Piek, C. J. (2024). Owners’ experiences of administering meglumine antimoniate injections to dogs with leishmaniosis: An online questionnaire study. Veterinary Record, 194(11). https://doi.org/10.1002/vetr.4089

Vancouver

de Jong MK, van Eijk D, Broere F, Piek CJ. Owners’ experiences of administering meglumine antimoniate injections to dogs with leishmaniosis: An online questionnaire study. Veterinary Record. 2024;194(11). doi:10.1002/vetr.4089

BibTeX
@article{deJong2024,
  author = {de Jong, Marja K and van Eijk, Demy and Broere, Femke and Piek, Christine J},
  title = {Owners’ experiences of administering meglumine antimoniate injections to dogs with leishmaniosis: An online questionnaire study},
  journal = {Veterinary Record},
  year = {2024},
  volume = {194},
  number = {11},
  doi = {10.1002/vetr.4089}
}
Kostenlos starten →